Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis

In the absence of comparative studies, guidelines consider neurokinin 1 receptor antagonists (RAs) as interchangeable. We evaluated the pooled efficacy from three cisplatin registration trials, each with arms containing netupitant/palonosetron (NEPA), a fixed neurokinin 1 RA (netupitant)/serotonin T...

Full description

Saved in:
Bibliographic Details
Published in:Future oncology (London, England) England), 2021-08, Vol.17 (23), p.3027-3035
Main Authors: Navari, Rudolph M, Binder, Gary, Bonizzoni, Erminio, Clark-Snow, Rebecca, Olivari, Silvia, Roeland, Eric J
Format: Article
Language:English
Subjects:
Administration, Oral
Adult
antiemetic
Antiemetics - administration & dosage
Antineoplastic Agents - adverse effects
aprepitant
Aprepitant - administration & dosage
CINV
cisplatin
Cisplatin - adverse effects
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Drug Administration Schedule
Drug Combinations
Female
highly emetogenic
Humans
Isoquinolines - administration & dosage
Male
Middle Aged
Multicenter Studies as Topic
Nausea - chemically induced
Nausea - epidemiology
Nausea - prevention & control
Neoplasms - drug therapy
NEPA
Pyridines - administration & dosage
Quinuclidines - administration & dosage
Randomized Controlled Trials as Topic
Vomiting - chemically induced
Vomiting - epidemiology
Vomiting - prevention & control
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In the absence of comparative studies, guidelines consider neurokinin 1 receptor antagonists (RAs) as interchangeable. We evaluated the pooled efficacy from three cisplatin registration trials, each with arms containing netupitant/palonosetron (NEPA), a fixed neurokinin 1 RA (netupitant)/serotonin Type 3 (5-HT3) RA (palonosetron) combination, and an aprepitant (APR) regimen. Efficacy data were pooled for rates of complete response (CR: no emesis/no rescue medication), complete protection (CR + no significant nausea), total control (CR + no nausea) and no significant nausea during acute (0–24 h), delayed (>24–120 h) and overall (0–120 h) phases post chemotherapy. Among 621 NEPA and 576 APR patients, response rates were similar for the acute phase, and generally favored NEPA during delayed and overall phases. CR rates for NEPA versus APR were 88.4 versus 89.2%, 81.8 versus 76.9% (p 
ISSN:1479-6694
1744-8301
DOI:10.2217/fon-2021-0023